A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

Abarelix Study Group, J Trachtenberg… - The Journal of …, 2002 - auajournals.org
Purpose: We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …
被引用次数：228 相关文章

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

J Trachtenberg, M Gittleman, C Steidle, W Barzell… - The Journal of …, 2002 - infona.pl
We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …

[引用][C] A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary

J TRACHTENBERG, M GITTLEMAN… - The Journal of …, 2002 - pascal-francis.inist.fr
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily
antiandrogen in men with prostate cancer. Commentary CNRS Inist Pascal-Francis CNRS Pascal …

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

J Trachtenberg, M Gittleman, C Steidle… - The Journal of …, 2002 - pubmed.ncbi.nlm.nih.gov
Purpose We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …

[引用][C] A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

J TRACHTENBERG, M GITTLEMAN, C STEIDLE… - The Journal of …, 2002 - cir.nii.ac.jp
A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus
Daily Antiandrogen In Men With Prostate Cancer | CiNii Research CiNii 国立情報学研究所 学術 …

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.

J Trachtenberg, M Gittleman, C Steidle… - The Journal of …, 2002 - europepmc.org
Purpose We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

J Trachtenberg, M Gittleman, C Steidle, W Barzell… - The Journal of …, 2002 - Elsevier
PURPOSE: We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …

[引用][C] A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

J TRACHTENBERG - J. Urol., 2002 - cir.nii.ac.jp
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus
daily antiandrogen in men with prostate cancer | CiNii Research CiNii 国立情報学研究所 …

[引用][C] A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary

J TRACHTENBERG, M GITTLEMAN, C STEIDLE… - The Journal of …, 2002 - Elsevier